Toll-like receptor 9; CD289 (TLR9)

From Aaushi
Jump to navigation Jump to search

Function

Structure

Compartment

membrane

Alternative splicing

named isoforms=5

Expression

Pharmacology

More general terms

References

  1. Entrez Gene http://www.ncbi.nlm.nih.gov/sites/entrez?db=gene&cmd=Retrieve&dopt=Graphics&list_uids=54106
  2. 2.0 2.1 UniProt http://www.uniprot.org/uniprot/Q9NR96.html
  3. Bankhead C Drug May Reverse Anti-PD-1 Resistance in Melanoma. Responses in 22% of resistant patients with TLR9 agonist. MedPage Today. April 19, 2018 https://www.medpagetoday.com/meetingcoverage/aacr/72435
    Milhem M, et al Intratumoral toll-like receptor 9 (TLR9) agonist, CMP-001, in combination with pembrolizumab can reverse resistance to PD-1 inhibition in a phase Ib trial in subjects with advanced melanoma. American Association for Cancer Research (AACR 2018) Abstract CT144

Database